🔗 Share this article

An underground market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.

Investigational Treatment Gaining Traction Via Social Media

The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Viewers are urged to message these profiles directly for source information, while also obtaining promotional offers.

Thriving Trade on Social Networks

Separately, a flourishing trade exists on Telegram, where communities with numerous of members share “before and after” photos, administration instructions and assertions of rapid British shipping. Vendors market the drug there before directing customers to other platforms for transactions.

Learning About The Experimental Drug

This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – GLP-1, GIP and glucagon. Preliminary studies suggest it could help individuals reduce up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed online as the next Ozempic.

Healthcare Professionals Express Worries

However, physicians and chemists have warned that the distribution of what remains an unlicensed medication in the UK is a cause for concern and could lead to users administering substances of uncertain source.

Several professionals stated the demand for retatrutide could be linked to the increasing price of licensed weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Marketing retatrutide on social media or Telegram is illegal in the United Kingdom, as it is an unapproved medication that cannot be marketed or supplied for human use under the British medical regulations.

Several influencers try to circumvent the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but advertising and distribution can still breach medicines, marketing, and consumer regulations, risking penalties, prosecution or imprisonment.

Platform Response and Material Removal

According to the social media company, the platform has removed problematic material and prohibited associated keywords and query recommendations. The company stated it was dedicated to keeping the service safe and allocating resources in strengthening compliance measures.

Digital Marketplace Activities

Research also found communities with up to 9,000 members marketing retatrutide using Telegram's integrated discovery tool, which operates like a online catalog. Typing “retatrutide” instantly brings up groups with numerous of members, filled with images of weight loss, glowing reviews and step-by-step guides for preparing or injecting at home.

After minutes of entering one community, a vendor shared WhatsApp details, where the majority of transactions occur. The vendor sent an instruction manual and guaranteed shipping within two days. When asked whether the substance was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one asked about weight, medical conditions or previous experience.

Product Information and Pricing

Inside these groups, posts show dark colored packages with Royal Mail stickers, claiming to include new batches. One message read: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, prepared at home with sterile water, or pre-filled pens usually sold at £160 for 20 milligrams. When asked how much time a injector should be used, sellers give conflicting responses varying between a several days to “depends on your body”.

Platform Oversight and Safety Measures

A spokesperson for Telegram stated it regularly moderated dangerous material on its platform including material that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting materials they cannot confirm. Even if the research behind this drug is valid, these online products may not contain what they advertise,” stated Jason Murphy, the head of pharmacy at Chemist4U.

A medical professional of an online medical service linked the increase in demand to recent cost increases for authorized slimming drugs such as Mounjaro. “With costs rising, individuals are using online platforms. But fake treatments are highly dangerous. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she said.

Her staff has previously seen individuals harmed by personal administration from unverified sources. “We recognize the disappointment, but buying from Telegram or WhatsApp is taking chances with your well-being,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”

Producer Position

A representative from the pharmaceutical company stated retatrutide was in phase 3 research studies and had not been reviewed or authorized by any government authority anywhere in the world. “Consequently at this time no one can sell [it] for human use,” they explained, noting that any item “falsely representing itself as a Lilly investigational substance not yet approved … may subject patients to possibly significant medical dangers”.